Burosumab-Twza Injection (Crysvita)

Burosumab (Crysvita) is covered for FDA‑approved treatment of X‑linked hypophosphatemia in patients ≥1 year but coverage is contingent on documented baseline hypophosphatemia (serum phosphorus and TmP/GFR below age/gender normal ranges) obtained prior to any XLH therapy—absence of these baseline labs limits/denies coverage. Initial 12‑month approval requires prescription by or consultation with an endocrinologist or nephrologist, weight‑based dosing (adults 1 mg/kg q4w; pediatrics 0.8 mg/kg q2w; doses rounded to nearest 10 mg, max 90 mg) and ongoing serum phosphorus monitoring with dose adjustments based on phosphorus levels.

"Treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.